Institutional members access full text with Ovid®

Share this article on:

New Drug to Treat HIV Infection

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: September 2011 - Volume 111 - Issue 9 - p 23
doi: 10.1097/01.NAJ.0000405055.38571.06
Drug Watch
  • A new nonnucleoside reverse-transcriptase inhibitor (NNRTI), rilpivirine (Edurant), has been approved for the treatment of HIV and AIDS.
  • Patients with an excessively high viral load shouldn't start taking rilpivirine because it will increase their risk of treatment failure; also, patients who've experienced treatment failure are more likely to develop resistance to other NNRTIs.
  • Rilpivirine should be taken with a meal for maximum absorption.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2011 Lippincott Williams & Wilkins, Inc.